Comparison
While Exenatide is used for type 2 diabetes treatment to improve glycemic control and modestly reduce body weight through GLP-1–like insulinotropic and glucagonostatic effects6768, PT-141 is FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women and is studied for sexual dysfunction in other populations, increasing sexual desire via CNS melanocortin pathways42101.
While Exenatide works as a 39-amino-acid exendin-4 peptide originally isolated from Gila monster venom that acts as a long-acting GLP-1 receptor agonist resistant to DPP-4 degradation67, PT-141 is the synthetic melanocortin receptor agonist bremelanotide, an analog of α-MSH that activates central MC3R and MC4R to modulate neuronal circuits governing sexual desire and arousal3242101.
Exenatide is 39 amino acids long, whereas PT-141 is shorter as it has a length of 7 amino acids. Exenatide is made up of a sequence of sequence data not available in the current dataset. PT-141 is made up of a sequence of sequence data not available in the current dataset.
Exenatide
Not assigned in the current dataset.
PT-141
POMC